Aromatase Inhibitor-Associated Joint Symptoms in Breast Cancer
Conditions
Interventions
Normal acupuncture group:Acupuncture/Normal acupucnture
Shllow/Sham acupucnture group:Shllow/Sham acupucnture
Control group:no intervention
Sponsors
First Affiliated Hospital of Nanjing Medical University, Jiangsu Privnce Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 70 years; 2. Post-surgical breast cancer patients with positive estrogen and progestin receptors; 3. Use third-generation aromatase inhibitors (anastrozole, letrozole or exemestane) more than 30 days; 4. Pain in bones, joints and muscle emerged or worsened after the use of AIs, or accompanied with hot flashes, night sweat, fatigue, depression, diminished sexual desire or declined quality of life; 5. The score of BPI-SF=3; 6. The score of KPS>70, the score of ECOG between 0 and 2.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women, or plan to have the baby in half a year; 2. Use of opioids or steroids and alternative/physical therapy for joint pain during the first 28 days of the study; 3. Use acupuncture in treating adverse effects caused by endocrine therapy during the first 3 months of the study; 4. Have the plan to be treated with surgery, chemotherapy, radiotherapy, immunotherapy and hormone therapy during the study; 5. Have a history of other malignancies in the past five years; 6. Have a history of bone metastasis, osteoarthritis, and rheumatoid arthritis; 7. Severe coagulation disorder; 8. Have a history of cardiovascular, liver, respiratory, renal, blood, endocrine, or neuropsychiatric disease with clinical symptoms; 9. Have a history of uncontrolled infection, inflammation, metabolic disease, or neuropathic joint disease; 10. Inappropriate to participate with the consideration of researchers. 5. Have a history of other malignancies in the past five years; 6. Have a history of bone metastasis, osteoarthritis, and rheumatoid arthritis; 7. Severe coagulation disorder; 8. Have a history of cardiovascular, liver, respiratory, renal, blood, endocrine, or neuropsychiatric disease with clinical symptoms; 9. Have a history of uncontrolled infection, inflammation, metabolic disease, or neuropathic joint disease; 10. Inappropriate to participate with the consideration of researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Brief Pain Inventory–Short Form; | — |
Secondary
| Measure | Time frame |
|---|---|
| Functional Assessment of Cancer Therapy-General; | — |
Countries
China
Contacts
Public ContactYin Yongmei
Outcome results
None listed